S-8

As filed with the Securities and Exchange Commission on November 5, 2019

Registration No. 333-

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM S-8

REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OF 1933

MorphoSys AG
(Exact name of registrant as specified in its charter)

Germany	Not Applicable
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

Semmelweisstrasse 7
82152 Planegg
Germany
Telephone: +49 89-89927-0
(Address of Principal Executive Offices)

RSU Plan October 1, 2019
(Full title of the plan)

_____________________

MorphoSys US Inc.

470 Atlantic Avenue, 14^th floor

Boston, MA 02210

(Name and Address of Agent For Service)

Tel: +1 (617) 273-8273

(Telephone Number, Including Area Code, of Agent For Service)

Copy to:

Stephan Hutter

Skadden, Arps, Slate, Meagher & Flom LLP

TaunusTurm

Taunustor 1

60310 Frankfurt am Main

Germany

Tel: +49 69 74220 0

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer □ Accelerated filer □  Non-accelerated filer ☑
(Do not check if a smaller reporting company) Smaller reporting company □

CALCULATION OF REGISTRATION FEE

Title of securities to be registered	Amount to be registered(1)	Proposed maximum offering price per share(2)	Proposed maximum aggregate offering price	Amount of registration fee
Ordinary Shares, no par value	127,357	$108.64	$13,836,065	$1,796

(1) This Registration Statement shall also cover any additional ordinary shares, no par value (“Ordinary Shares”) of MorphoSys AG (the “Company”), that become issuable in respect of the securities identified in the above table by reason of any share dividend, share split, recapitalization or other similar transaction effected without the receipt of consideration which results in an increase in the number of Ordinary Shares registered hereunder.

(2) Pursuant to Rule 457(h) under the Securities Act, the proposed maximum offering price of the Ordinary Shares being registered hereby is not known and has been determined in accordance with Rule 457(h)(1) and 457(c) based on the average high and low price of the Ordinary Shares on October 30, 2019.

PART I.

INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS

All information required by Part I to be contained in the Section 10(a) prospectus is omitted from this Registration Statement in accordance with Rule 428 under the Securities Act of 1933 (the “Securities Act”) and the Note to Part I of Form S-8.

PART II.

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3. Incorporation of Documents by Reference.

The following documents filed with or furnished to the Securities and Exchange Commission (the “Commission”) by the Registrant are incorporated herein by reference:

(a) The Registrant’s Annual Report on Form 20-F filed with the Commission on March 13, 2019; and

(b) The description of the Registrant’s ordinary shares incorporated by reference in the Registrant’s registration statement on Form 8-A (File No. 001-38455) filed with the Commission on April 12, 2018.

All documents subsequently filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”), and, to the extent designated therein, certain reports on Form 6-K the Registrant submits to the Commission after the date hereof, prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the date of filing of such documents. Any statement contained herein or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document that is or is deemed to be incorporated by reference herein modifies or supersedes such previous statement. Any statement so modified or superseded shall not be deemed to constitute a part of this Registration Statement, except as so modified or superseded.

Item 4. Description of Securities.

Not applicable.

Item 5. Interests of Named Experts and Counsel.

Not applicable.

Item 6. Indemnification of Directors and Officers.

Under German law, the Registrant may not, as a general matter, indemnify members of its management board and supervisory board. Certain limited exceptions may apply if the indemnification is in the legitimate interest of the Registrant. The Registrant will indemnify our management board and supervisory board members, to the extent permissible under German law, from and against any liabilities arising out of or in connection with their services for the Registrant.

The Registrant provides directors’ and officers’ liability insurance for the members of its management and supervisory boards against civil liabilities, including liability under the Securities Act, which they may incur in connection with their activities on behalf of the Registrant.

Item 7. Exemption from Registration Claimed.

Not Applicable.

Item 8. Exhibits.

The list of exhibits is set forth under “Index of Exhibits” at the end of this registration statement and is incorporated herein by reference.

Item 9. Undertakings.

(a) The undersigned Registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

(i)  to include any prospectus required by Section 10(a)(3) of the Securities Act;

(ii)  to reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement; and

(iii)  to include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) shall not apply if the information required to be included in a post-effective amendment of this Registration Statement by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto authorized, in the city of Planegg, Germany on this, the 5th day of November 2019.

MorphoSys AG

By: /s/ Dr. Jean-Paul Kress                   

Name: Dr. Jean-Paul Kress

Title: Chief Executive Officer

POWER OF ATTORNEY

Each person whose signature appears below constitutes and appoints Dr. Jean-Paul Kress and Jens Holstein, and each of them singly, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them singly, for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 of MorphoSys AG, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting to the attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in or about the premises, as full to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his substitutes, may lawfully do or cause to be done by virtue hereof. This power of attorney may be executed in counterparts.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons, in the capacities indicated and on the 5th day of November 2019.

[Signature page to follow]

Signature	Title
/s/ Dr. Jean-Paul Kress	Chief Executive Officer
Name: Dr. Jean-Paul Kress
/s/ Jens Holstein	Chief Financial Officer and Principal
Name: Jens Holstein	Accounting Officer
/s/ Dr. Marc Cluzel	Chairman of the Supervisory Board
Name: Dr. Marc Cluzel
/s/ Dr. Frank Morich	Deputy Chairman of the Supervisory Board
Name: Dr. Frank Morich
/s/ Krisja Vermeylen	Member of the Supervisory Board
Name: Krisja Vermeylen
/s/ Wendy Johnson	Member of the Supervisory Board
Name: Wendy Johnson
/s/ Dr. George Golumbeski	Member of the Supervisory Board
Name: Dr. George Golumbeski
/s/ Michael Brosnan	Member of the Supervisory Board
Name: Michael Brosnan
/s/ Sharon Curran	Member of the Supervisory Board
Name: Sharon Curran
/s/ David Trexler	Authorized Representative in the United States
Name: David Trexler

INDEX OF EXHIBITS

Exhibit Number Description

4.1 Articles of Association of MorphoSys AG (incorporated herein by reference to Exhibit 3.1 to the registration statement on Form F-1, as amended (File No. 333-223843))

4.2 Specimen Certificate for Global Shares of the Registrant (incorporated herein by reference to Exhibit 4.2 to the registration statement on Form F-1, as amended (File No. 333-223843))

4.3 Restricted Stock Unit Program 2019 (US Inc.)

5.1 Opinion of Charlotte Lohmann and Klaus de Wall

23.1 Consent of Independent Registered Public Accounting Firm

23.2 Consent of Charlotte Lohmann and Klaus de Wall (included in the opinion filed as Exhibit 5.1)

24.1 Power of Attorney (included on the signature page of this Registration Statement)

EX-4.3

Exhibit 4.3

	MorphoSys AG
	Semmelweisstraße 7
	82152 Planegg
	Germany
	Telefon:	+49 (0)89 899 27-0
	Fax:	+49 (0)89 899 27-222
	Email:	info@morphosys.com
	Internet:	www.morphosys.com
RSUP 2019 (US Inc.)
	MorphoSys US Inc.
	470 Atlantic Avenue
	Boston, MA 02210
	USA

Restricted Stock Unit Program 2019 (US Inc.) for senior managers and employees (including directors and officers) of MorphoSys US Inc.

Introduced by decision of the Vorstand of MorphoSys AG, with the consent of the Supervisory Board of MorphoSys AG, as of 1 October 2019

- Terms and Conditions -

MorphoSys AG

Semmelweisstraße 7

82152 Planegg

Germany

MorphoSys US Inc.

470 Atlantic Avenue

Boston, MA 02210

USA

Vorstand Dr. Jean-Paul Kress (Vorsitzender), Dr. Markus Enzelberger, Jens Holstein, Dr. Malte Peters Vorsitzender des Aufsichtsrats Dr. Marc Cluzel Bankverbindung Commerzbank BLZ: 700 800 00 Kto.: 0349775600 IBAN: DE73 7008 0000 0349 7756 00 SWIFT (BIC): DRESDEFF700 St.-Nr. 9143/101/21259 USt-ID. Nr. DE 15506 9821     Sitz der Gesellschaft Planegg, Landkreis München Handelsregister AG München HRB 121023    

TABLE OF CONTENT

TABLE OF CONTENT		2
DEFINITIONS		3
RECITALS		4
§ 1	ELIGIBILITY	5
§ 2	PLAN VOLUME AND GRANT OF RSUs	5
§ 3	WAITING PERIOD, ANNUAL CYCLE AND VESTING	6
§ 4	KEY PERFORMANCE INDICATORS	7
§ 5	CONSEQUENCES OF A TERMINATION OF EMPLOYMENT	10
§ 6	CASH PAYMENT CLAIM RESULTING FROM RSUs AND SETTLEMENT OF RSUs	11
§ 7	TRANSFERABILlTY	14
§ 8	CHANGE OF CONTROL	14
§ 9	ADJUSTMENT IN CASE OF SPECIFIC CAPITAL AND OTHER STRUCTURAL MEASURES	16
§ 10	EXTRAORDINARY DEVELOPMENTS	17
§ 11	INSIDER TRADING AND BLACK-OUT PERIODS	17
§ 12	LIMITATION OF LIABILITY	18
§ 13	TAXES, SOCIAL SECURITY AND COSTS	19
§ 14	FORM REQUIREMENTS	20
§ 15	PROCESSING OF PERSONAL DATA	21
§ 16	GOVERNING LAW AND JURISDICTION	21
§ 17	FINAL PROVISIONS	21

Page2/26

DEFINITIONS

Adjustment Event	16	Insider Trading Rules	17
Annual Cycle	7	KPI	7
Annual Cycles	7	KPI Achievement Rate	8
Authorized Capital 2019-I	4	KPIs	7
Award Agreement	5	Leaver	11
Award Amount	5	MorphoSys	4
Award Date	6	MorphoSys US	4
Award Period	6	Notices	20
Black-Out Periods	18	Officers	4
Board of Directors	5	Overall KPI Achievement Rate	9
Cap	9	Participant	5
Capital Increase Resolution Date	12	Revenue KPI	8
Cash Payment Claim	11	Revenue KPI Achievement Rate	9
Cash Settlement	12	Revenue Performance	8
Cash Settlement Date	12	RSU	4
Change of Control	14	RSUP 2019 (US Inc.)	4
Company	4	RSUP Resolution	4
Conversion	5	RSUP Terms & Conditions	4
Data Subjects	24	RSUs	4
Directors	4	Share Price KPI	8
EBIT KPI	7	Share Price KPI Achievement Rate	9
EBIT KPI Achievement Rate	9	Share Price Performance	8
EBIT Performance	8	Share Settlement	12
Employees	4	Share Settlement Date	12
Euro Award Amount	5	Shares	4
External Service Provider	25	Termination Date	11
Extraordinary Events or Developments	17	Transaction	17
GDPR	24	Vested RSUs	7
Hurdle	9	Waiting Period	6
Initial Number of RSUs	6	Waiting Period Expiration Date	6

Page3/26

RECITALS

An attractive and competitive remuneration program is essential for the recruitment and long-term commitment of highly qualified employees.

In JuIy 2018, MorphoSys AG (“MorphoSys” or the “Company”) has founded a 100% subsidiary in the USA, MorphoSys US Inc. (“MorphoSys US”). As part of MorphoSys’ intention to develop a strong presence in the USA and recruit and retain highly qualified employees at MorphoSys US, a share-based employee participation program is required which takes into account US standards and expectations.

Therefore, MorphoSys intends to implement a “Restricted Stock Unit Program” (the “RSUP 2019 (US Inc.)”) as a long-term remuneration component for senior managers and employees of MorphoSys US (including directors of MorphoSys US (“Directors”) and officers of MorphoSys US (“Officers”)) (senior managers and employees of MorphoSys US, including Directors and Officers hereinafter collectively the “Employees”). Under the RSUP 2019 (US Inc.), the Company shall be allowed to grant so-called “Restricted Stock Units” (“RSUs” and each a “RSU”) to the Employees, which – if certain requirements are met – grant the Employees a claim against the Company for a cash payment, the amount of which depends, amongst others, on the stock exchange price of the shares of the Company (the “Shares”). However, the RSUP 2019 (US Inc.) shall include a substitution right of the Company, permitting it to fulfil the payment claims of the Employees resulting from the RSUs by delivering Shares instead of cash.

With resolution dated 22 May 2019, the Company’s General Meeting (Hauptversammlung) has authorized the Management Board (Vorstand), with the consent of the Supervisory Board (Aufsichtsrat), until 30 April 2024 (including) to increase the Company’s registered share capital by up to € 159,197.00 against cash contributions and/or contributions in kind once or several times by issuing up to 159,197 new no-par value bearer Shares (auf den Inhaber lautende Stückaktien) (“Authorized Capital 2019-I”). The Authorized Capital 2019‑I only serves the purpose of delivering Shares of the Company against the contribution of cash payment claims resulting from RSUs, in order to settle RSUs that were granted to Employees.

The present terms and conditions (the “RSUP Terms & Conditions”) establish the rules pursuant to which the RSUs under the RSUP 2019 (US Inc.) can be granted and settled.

Page4/26

§ 1
ELIGIBILITY

1.1 RSUs can be granted to Employees (each a “Participant”).

1.2 Persons who, at the same time to being an Employee, are members of the Company’s Management Board, or are an employee of the Company, are not eligible to participate in the RSUP 2019 (US Inc.).

1.3 Eligibility as a Participant is determined by the Company’s Management Board. The President of MorphoSys US, together with the board of directors of MorphoSys US (“Board of Directors”) may propose certain Employees to the Company’s Management Board to become eligible as a Participant.

§ 2
PLAN VOLUME AND GRANT OF RSUs

2.1 Under the RSUP 2019 (US Inc.), up to an aggregate of 127,357RSUs may be granted. RSUs that are forfeited pursuant to the RSUP Terms & Conditions will once again be available for future grants.

2.2 The Company’s Management Board will determine an individual USD award amount (the “Award Amount”) to be granted to a Participant by MorphoSys US by way of a separate award agreement (“Award Agreement”) and such Award Amount will be converted into a certain number of RSUs.

2.3 With respect to the conversion of the Award Amount into RSUs, i.e., to calculate the exact number of RSUs to be allocated to a Participant, the respective Award Amount must, in a first step, be converted into a respective amount in Euros (the “Conversion”). The Conversion shall be based on the Euro foreign exchange reference rate, as published on the official website of the European Central Bank (ECB) on the Award Date (as defined in § 2.5) (the “Euro Award Amount”). In a second step, the Euro Award Amount is divided by the average closing price (Schlusskurs) of the Shares on the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse) in Xetra trading (or a comparable successor system) on the 30 (thirty) trading days prior to the Award Date (as defined in § 2.5) (exclusive), rounded down to the nearest whole number; the number

Page5/26

resulting from such calculation (step one and step two) equals the number of RSUs to be allocated to a Participant (the “Initial Number of RSUs”). If a closing auction does not take place on the relevant trading day(s) or a price is not determined in the auction, the applicable price will be the last price quoted in continuous trading, provided there was continuous trading on that trading day.

For example: If a Participant is granted an Award Amount of USD 100,000.00 and the USD/EUR exchange rate on the Award Date is 1 USD = 0.9060 EUR, then the Euro Award Amount amounts to EUR 90,600 (100,000 x 0.9060). If the average closing price (Schlusskurs) of the Shares on the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse) in Xetra trading on the 30 trading days prior to the Award Date amounted to EUR 105.00, then the Initial Number of RSUs to be allocated to the Participant would amount to 862 (EUR 90,600 / EUR 105.00 = 862.85, rounded down to the nearest whole number).

2.4 RSUs can be awarded in accordance with legal requirements in each case on 1 April and, in exceptional cases, on 1 October of the respective business year of the Company (the “Award Period”), subject to a continuing and non-terminated (ungekündigt) service relationship or employment of the relevant Participant with MorphoSys US at the relevant Award Date (as defined in § 2.5).

2.5 The date on which the Award Agreement becomes effective (the “Award Date”) shall be the date on which the Participant receives the offer to conclude the Award Agreement (irrespective of the point in time the offer to conclude the Award Agreement is accepted), unless the Award Agreement specifies an earlier or a later date as Award Date.

§ 3
WAITING PERIOD, ANNUAL CYCLE AND VESTING

3.1 Each RSU is subject to a waiting period of three (3) years (“Waiting Period”), which shall commence on the day of the Award Date at 00:00 hours (beginning of the day) and end on the day prior to the third anniversary of the Award Date at 24:00 hours (midnight) (“Waiting Period Expiration Date”).

Page6/26

For example: If the Award Date is 1 October 2019, the Waiting Period would start on 1 October 2019 at 00:00 hours (beginning of the day) and end on 30 September 2022 at 24:00 hours (midnight).

3.2 The Waiting Period is divided into three annual cycles (“Annual Cycles”). The first Annual Cycle will commence on the day of the Award Date at 00:00 hours (beginning of the day) and end on the day prior to the first anniversary of the Award Date at 24:00 hours (midnight), the second Annual Cycle will commence on the day of the first anniversary of the Award Date at 00:00 hours (beginning of the day) and end on the day prior to the second anniversary of the Award Date at 24:00 hours (midnight) and the third Annual Cycle will commence on the day of the second anniversary of the Award Date at 00:00 hours (beginning of the day) and end on the day prior to the third anniversary of the Award Date at 24:00 hours (midnight) (each an “Annual Cycle”).

3.3 One third (1/3) of the Initial Number of RSUs will vest at the end of each Annual Cycle subject to the following conditions: (i) the achievement of certain KPIs (§ 4) and (ii) no forfeiture of RSUs pursuant to § 5 (the “Vested RSUs”).

3.4 After expiry of the Waiting Period and an administration period in which to determine the settlement amounts, the Company will settle the total number of Vested RSUs; provided, that such settlement shall occur no later than 90 days following the Waiting Period Expiration Date.

§ 4
KEY PERFORMANCE INDICATORS

4.1 With respect to an Annual Cycle, RSUs will vest only if and to the extent the KPIs (as defined in § 4.2) have been reached or exceeded in accordance with the following provisions.

4.2 Key Performance Indicators (“KPIs”, and each a “KPI”) are:

4.2.1 the EBIT performance of MorphoSys US over the fiscal year in which an Annual Cycle starts, measured and evaluated in relation to the EBIT Performance (as defined in § 4.3) set by the Board of Directors, with the consent of the Company’s Management Board (“EBIT KPI”);

Page7/26

4.2.2 the revenue performance of MorphoSys US over the fiscal year in which an Annual Cycle starts, measured and evaluated in relation to the Revenue Performance (as defined in § 4.3) set by the Board of Directors, with the consent of the Company’s Management Board (“Revenue KPI”); and

4.2.3 the performance of the stock exchange price of the Shares on the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse) in Xetra trading (or a comparable successor system) over the Annual Cycle, measured and evaluated in relation to the Share Price Performance (as defined in § 4.3) set by the Board of Directors, with the consent of the Company’s Management Board (“Share Price KPI”).

For example: If an Annual Cycle starts on 1 October 2019, the KPIs will be measured and evaluated on the basis of the EBIT performance and the revenue performance during the fiscal year starting 1 January 2019 through 31 December 2019 and the share price performance will be measured and evaluated on the basis of the share price performance during 1 October 2019 until September 30, 2020. If the second Annual Cycle starts on 1 October 2020, the KPIs will be measured and evaluated on the basis of the EBIT performance and the revenue performance during the fiscal year starting 1 January 2020 through 31 December 2020 and the share price performance will be measured and evaluated on the basis of the share price performance during 1 October 2020 until 30 September 2021. If the third Annual Cycle starts on 1 October 2021, the KPIs will be measured and evaluated on the basis of the EBIT performance and the revenue performance during the fiscal year starting 1 January 2021 through 31 December 2021 and the share price performance will be measured and evaluated on the basis of the share price performance during 1 October 2021 until 30 September 2022.

4.3 The Board of Directors, with the consent of the Company’s Management Board, will determine the performance to be achieved for each KPI with respect to a certain Annual Cycle (respectively the “EBIT Performance”, the “Revenue Performance” and the “Share Price Performance”) and which will, depending on the degree of achievement (as a percentage) of each KPI, correspond with a certain “KPI Achievement Rate” for the

Page8/26

respective Annual Cycle, respectively the “EBIT KPI Achievement Rate”, the “Revenue KPI Achievement Rate”  and the “Share Price KPI Achievement Rate” for the respective Annual Cycle. If the KPI Achievement Rate for any of the KPIs exceeds 125.00%, the respective KPI Achievement Rate will nevertheless be 125.00% (“Cap”).

4.4 Once the Board of Directors, with the consent of the Company’s Management Board, has determined the KPIs for a certain Annual Cycle pursuant to section 4.3, the Participant will be provided with such information substantially in the form as set out in Exhibit 2 attached hereto.

4.5 The “Overall KPI Achievement Rate” for a respective Annual Cycle will be the arithmetic mean (rounded commercially to the nearest whole number) of (i) the EBIT KPI Achievement Rate, (ii) the Revenue KPI Achievement Rate and the (iii) Share Price KPI Achievement Rate, each of which will be determined in accordance with the KPIs that will be provided to a Participant for each Annual Cycle in accordance with § 4.4.

For example: If the EBIT KPI Achievement Rate for an Annual Cycle is 75%, the Revenue KPI Achievement Rate is 35% and the Share Price KPI Achievement Rate is 135%, the Overall KPI Achievement Rate will be calculated as follows:

Note: In accordance with § 4.3, the Share Price KPI Achievement Rate was capped at 125%.

(75% + 35% + 125%) / 3 = 78.333%, i.e. 78% (rounded commercially to the nearest whole number).

4.6 The number of Vested RSUs at the end of an Annual Cycle will be calculated by multiplying (i) one third (1/3) of the Initial Number of RSUs allocated to a Participant with (ii) the Overall KPI Achievement Rate, provided, however, that at least an Overall KPI Achievement Rate of 50.00% must be reached (“Hurdle”), otherwise the number of Vested RSUs for the respective Annual Cycle will be 0.

The following chart illustrates the number of RSUs that vest at the end of an Annual Cycle pursuant to this § 4, depending on the degree of achievement of the Overall KPI Achievement Rate:

Page9/26

Overall KPI Achievement Rate	Calculation of total number of Vested RSUs for one Annual Cycle
0%	Vested RSUs at the end of an Annual Cycle = 0, given that the hurdle of a minimum Overall KPI Achievement Rate of at least 50.00% has not been reached
1%
2%
3%
[etc.]
48%
49%
< 50.00%
50.00% (hurdle)	[1/3 of Initial Number of RSUs] x 50.00%
60%	[1/3 of Initial Number of RSUs] x 60%
70%	[1/3 of Initial Number of RSUs] x 70%
[etc.]	[etc.]
120%	[1/3 of Initial Number of RSUs] x 120%
125%	[1/3 of Initial Number of RSUs] x 125%

4.7 After the expiry of the Waiting Period, the Vested RSUs for each Annual Cycle are added to calculate the total number of Vested RSUs.

For example: If the Initial Number of RSUs granted to a Participant was 300 and during the first Annual Cycle an Overall KPI Achievement Rate of 80% was achieved, during the second Annual Cycle an Overall KPI Achievement Rate of 40% was achieved, and during the third Annual Cycle an Overall KPI Achievement Rate of 125% (Cap) was achieved, the number of Vested RSUs at the end of the first Annual Cycle is 80 (1/3 of the 300 granted RSUs x 80%), the number of Vested RSUs at the end of the second Annual Cycle is 0 (since the minimum Hurdle of 50% was not achieved) and the number of Vested RSUs at the end of the third Annual Cycle is 125 RSUs (1/3 of the 300 granted RSUs x 125%). Thus, after expiry of the Waiting Period, the total Vested RSUs that will be settled would be 205 (80 + 0 + 125).

§ 5
CONSEQUENCES OF A TERMINATION OF EMPLOYMENT

5.1 With respect to an Annual Cycle, RSUs will vest only if the Participant still has an active employment relationship with MorphoSys US at the end of the relevant Annual Cycle.

Page10/26

5.2 If a Participant’s employment at MorphoSys US terminates for any reason (such that the Participant is no longer an Employee) during an Annual Cycle (such Participant a “Leaver”), such Leaver will retain the RSUs that have already vested pursuant to § 3.3 and § 4 with respect to any Annual Cycle completed before the date of the Participant’s effective termination of employment (the “Termination Date”). Any additional RSUs that were granted to such Leaver and that have not vested will not continue to vest following the Termination Date and instead, they shall be forfeited by the Participant on the Termination Date without any compensation or other consideration paid therefor. No partial vesting will take place with respect to any Annual Cycle that is in effect at the time a Termination Date occurs. Any retained RSUs that were vested as of the Participant’s Termination Date shall be paid following the Waiting Period Expiration Date, consistent with § 6, below.

5.3 For example: If a Participant is notified of a termination of his employment with MorphoSys US in the example in § 4.7 in the first Annual Cycle, and such termination has a Termination Date that occurs during the second Annual Cycle of the Waiting Period, such Participant will retain the 80 Vested RSUs from the first Annual Cycle; however, the remaining 200 RSUs originally granted to such Participant (applicable to the second and third Annual Cycles) will be forfeited on the Termination Date without compensation or other consideration paid to the Participant. No further vesting of the Participant’s award of RSUs will occur at the end of the second or third Annual Cycles.

§ 6
CASH PAYMENT CLAIM RESULTING FROM RSUs AND SETTLEMENT OF RSUs

6.1 Upon expiration of the Waiting Period, each Vested RSU shall entitle the Participant to a cash payment claim (the “Cash Payment Claim”) against the Company in the amount of the closing price (Schlusskurs) of the Shares on the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse) in Xetra trading (or a comparable successor system) (i) in case of a Cash Settlement (as defined in § 6.2), on the Cash Settlement Date (as defined in § 6.2) or, (ii) in case of a Share Settlement (as defined in § 6.3), on the day of the resolution of the Company’s Management Board to utilize, with the consent of the Company’s Supervisory Board, the Authorized Capital

Page11/26

2019-I against contribution in kind (the “Capital Increase Resolution Date”). If a closing auction does not take place on the relevant trading day(s) or a price is not determined in the auction, the applicable price will be the last price quoted in continuous trading, provided there was continuous trading on that trading day.

6.2 Within 90 days following the Waiting Period Expiration Date, the Company will settle the Vested RSUs as determined by the Company in its sole discretion by fulfilling the Cash Payment Claim (i) by way of an effective cash payment to a bank account designated to the Company by the respective Participant in advance (the “Cash Settlement”), or (ii) by transferring Shares to the Participant in accordance with § 6.3, or (iii) by a combination of both. In case of a Cash Settlement, the Company will convert the Cash Payment Claim, denominated in Euros, into a USD amount, based on the Euro foreign exchange reference rate, as published on the official website of the European Central Bank (ECB) on the actual date (within 90 days following the Waiting Period Expiration Date) on which such payment is made (the “Cash Settlement Date”).

6.3 In the event of a settlement in the form of Shares, whereby Shares are created from a capital increase out of the Authorized Capital 2019-I (Kapitalerhöhung aus Genehmigtem Kapital 2019-I), the respective contribution in kind (Sacheinlage) for the new Shares shall be the Cash Payment Claim (denominated in EUR) resulting from the Vested RSUs. The Cash Payment Claim (denominated in EUR) will then – in the course of the capital increase – be contributed by the Participant to the Company against issuance of one (1) new Share for each one (1) Vested RSU (the “Share Settlement”). In the event of a Share Settlement, the Participant will be required to take all measures necessary to effect the Share Settlement, including, for example, the opening of an account to which the Shares may be booked, the conclusion of a contribution agreement with the Company and/or the subscription of the new Shares to be issued to the Participant by way of a subscription certificate. The actual date (within 90 days following the Waiting Period Expiration Date) on which the new Shares, which were created from the capital increase against contribution in kind, are transferred to the securities’ account of the respective Participant, the “Share Settlement Date”.

Page12/26

For example: If the Waiting Period Expiration Date for the 205 Vested RSUs in the example in § 4.7 occurs on 30 September 2022, the Company may decide, in its sole discretion, whether to settle the 205 Vested RSUs by way of a Cash Settlement or a Share Settlement:

(a) In case of a Cash Settlement, the Company will identify the closing price (Schlusskurs) of the Shares on the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse) in Xetra trading (or a comparable successor system) on the Cash Settlement Date. Assuming, on the Cash Settlement Date, the closing price (Schlusskurs) amounted to EUR 125.00, the Participant’s Cash Payment Claim resulting from the 205 Vested RSUs would amount to EUR 25,625.00. Assuming the EUR/USD exchange rate on the Cash Settlement Date is 1 EUR = 1.1500 USD, the Cash Payment Claim the respective Participant is entitled to would amount to USD 29,468.75.

(b) In case of a Share Settlement, the Company will request certain information from the Participant, which is necessary to perform the Share Settlement. Once the information has been provided by the Participant to the Company, and following the expiry of the Waiting Period, the Company will identify the closing price (Schlusskurs) of the Shares on the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse) in Xetra trading (or a comparable successor system) on the Capital Increase Resolution Date. Assuming, on the Capital Increase Resolution Date, the closing price (Schlusskurs) amounted to EUR 125.00, the Participant’s Cash Payment Claim resulting from the 205 Vested RSUs would amount to EUR 25,625.00. Following such determination, the Company’s Management Board, with the consent of the Supervisory Board, shall resolve to issue 205 new Shares by way of a capital increase in the context of which the Company’s share capital will be increased by EUR 205.00 against contribution in kind of the Cash Payment Claim of the Participant in the aggregate amount of EUR 25,625.00. Following the registration of the consummation of the capital increase, the 205 new Shares will be transferred to a security deposit of the Participant on the Share Settlement Date.

6.4 The Company will inform the Participant whether it will make use of the Cash Settlement (as defined in § 6.2) or the Share Settlement (as defined in § 6.3) or a combination of both in advance of the settlement.

Page13/26

§ 7
TRANSFERABILlTY

7.1 Neither the RSUs nor the rights of any Participant under any RSU or under the RSUP 2019 (US Inc.) are assignable or otherwise transferable except as provided in this § 7.

7.2 The RSUs are transferable only by will or applicable laws of descent upon the death of the relevant Participant.

§ 8
CHANGE OF CONTROL

8.1 For purposes of this § 8, “Change of Control” means the occurrence of any of the following events:

8.1.1 if any person or entity becomes the “Beneficial Owner” (as defined in Rule 13d-3 under the Securities Exchange Act of 1934), directly or indirectly, of securities of MorphoSys US representing 50% or more of the total voting power represented by MorphoSys US’s then outstanding voting securities (excluding for this purpose the Company’s or its affiliates or any employee benefit plan of the Company or its affiliates);

8.1.2 a merger or consolidation of MorphoSys US, whether or not approved by the Company's Board, other than a merger or consolidation which would result in the voting securities of MorphoSys US outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or the parent of such corporation) more than 50% of the total voting power represented by the voting securities of MorphoSys US or such surviving entity or parent of such corporation outstanding immediately after such merger or consolidation; or

8.1.3 the sale or disposition by MorphoSys US of all or substantially all of MorphoSys US’s assets in a transaction requiring stockholder approval.

Page14/26

Notwithstanding anything to the contrary herein, the terms Change of Control shall have a meaning that is consistent with the definition of change in control event, change in ownership or change in effective control set forth in Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), but only to the extent that it is necessary to comply with Code Section 409A.

8.2 In case a Change of Control occurs during the Waiting Period, § 3.3 shall be amended such that the RSUs shall vest immediately upon the Change of Control, with the calculation of the Overall KPI Achievement Rate to be determined as follows:

8.2.1 With respect to Annual Cycles that are already complete at the date when the Change of Control occurs:

(i) if the Overall KPI Achievement Rate exceeds 100% with respect to Annual Cycles that have concluded prior to the Change of Control, then the actual percentage shall apply with respect to the Overall KPI Achievement Rate for such completed Annual Cycles;

(ii) if the Overall KPI Achievement Rate is below 100% with respect to Annual Cycles that have concluded prior to the Change of Control, then the Overall KPI Achievement Rate for such concluded Annual Cycles shall nevertheless be 100%, provided that the Hurdle for such Annual Cycle(s) has been met.

8.2.2 With respect to the Annual Cycle during which the Change of Control occurs, as well as for subsequent Annual Cycles that have not yet commenced, as of the date the Change of Control occurs, the Overall KPI Achievement Rate shall be 100% for such Annual Cycle(s), irrespective of the achievement (if any) of the KPIs.

8.3 Notwithstanding anything herein to the contrary, all RSUs that vest upon the Change of Control shall be settled only after the Waiting Period has expired and shall be settled in accordance with § 6.

Page15/26

§ 9
ADJUSTMENT IN CASE OF SPECIFIC CAPITAL AND OTHER
STRUCTURAL MEASURES

9.1 In the event of:

9.1.1 a capital increase from Company funds by the issue of new shares (Kapitalerhöhung aus Gesellschaftsmitteln);

9.1.2 a reduction in the number of Shares by merging Shares without capital reduction (reverse share split) or an increase in the number of Shares without capital increase (share split);

9.1.3 a capital reduction (Kapitalherabsetzung) with a change in the total number of Shares issued by the Company; or

9.1.4 any other such event having an effect similar to any of the foregoing (each an “Adjustment Event”),

the Company’s Management Board may – subject to mandatory law – establish financial equality for the Participants to the extent necessary to prevent that such Adjustment Event results in a dilution or enlargement of the benefits or potential benefits resulting from the granted RSUs. In such an Adjustment Event the financial equality shall preferably be established by adjusting the number of RSUs.

9.2 For the avoidance of doubt: No adjustment pursuant to § 9.1 shall occur in the event of:

9.2.1 a capital increase from Company funds without the issue of new Shares (Kapitalerhöhung aus Gesellschaftsmitteln ohne Ausgabe neuer Aktien); or

9.2.2 a capital reduction without a change in the total number of Shares issued by the Company.

9.3 If an adjustment occurs in accordance with this § 9, fractions of shares will not be granted upon the settlement of RSUs nor will they be compensated by a payment in cash.

Page16/26

§ 10
EXTRAORDINARY DEVELOPMENTS

10.1 For purposes of this § 10, “Extraordinary Events or Developments” means – subject always to mandatory law – situations where the potential gain realized by the Participant upon the settlement of RSUs (i) is caused by unusual external events and developments; and (ii) cannot be reasonably justified under any circumstances by the development or business perspective of the Company, also taking into account international remuneration and incentive standards. However, the settlement of RSUs by a Participant as such, that results in an economic benefit for the Participant, does not constitute an Extraordinary Event or Development.

10.2 In case of Extraordinary Events or Developments, the Company’s Management Board is entitled to adjust in its discretion (pflichtgemäßes Ermessen) the payout in the form of a Cash Settlement or Share Settlement, to the extent required to eliminate such extraordinary effects.

§ 11
INSIDER TRADING AND BLACK-OUT PERIODS

11.1 Any transaction in the Shares granted in case of a Share Settlement (each a “Transaction”) must be conducted in compliance with (i) all applicable insider trading laws and regulations, namely Art. 14, 7 et seqq. MAR, and (ii) all provisions of any insider trading rules established by the Company ((i) and (ii) together the “Insider Trading Rules”). Each Participant is personally responsible for informing himself about, and acting in full compliance with, all applicable Insider Trading Rules. Any individual non-compliance with applicable Insider Trading Rules may lead to the imposition of civil and criminal penalties (as the case may be).

11.2 The Company may postpone or delay the settlement of any Vested RSUs by way of a Cash Settlement or Share Settlement or a combination of both to a later point in time due to restrictions under applicable laws and regulations or rejections from competent authorities.

11.3 In order to minimize the potential for prohibited insider trading, the Management Board of the Company may establish in its sole discretion

Page17/26

periods from time to time during which all or some of the Participants may not engage in transactions involving Shares granted in case of a Share Settlement (the “Black-Out Periods”). As a matter of precaution, and notwithstanding any other provisions in these RSUP Terms & Conditions, the Participants may not subscribe any new Shares during an applicable Black-Out Period.

§ 12
LIMITATION OF LIABILITY

12.1 The Company (nor any of its management board members, supervisory board members or employees) does not:

12.1.1 assume any responsibility or liability for the development of MorphoSys US’s EBIT and/or revenue or for the development of the value or market price of the Company’s Shares;

12.1.2 assume any responsibility or liability for the development of the value or market price of the Company’s Shares, including during the Waiting Period and during the period between the Waiting Period Expiration Date and, as the case may be, the Cash Settlement Date, the Capital Increase Resolution Date, or the Share Settlement Date;

12.1.3 warrant, assure or guarantee a profit of a Participant from the RSUP 2019 (US Inc.) or any RSU granted thereunder; or

12.1.4 warrant, assure or guarantee any increase in value of the RSUs or, following a Share Settlement, the value or market price of the Company’s Shares; in particular it is neither warranted, assured or guaranteed that a Participant will be able to sell his participation in the Company with a profit in the future, nor that no loss will be incurred.

12.2 Each Participant declares with his/her participation in the RSUP 2019 (US Inc.) that the participation is voluntary. Each Participant is aware of the fact that he/she alone bears the risk of a decrease in or total loss of value of the RSUs or, following a Share Settlement, the Company’s Shares. Each Participant accepts the offer to participate in the RSUP 2019 (US Inc.) at his/her own risk and assumes any liability relating thereto.

Page18/26

12.3 Each Participant accepts, that his/her claim stemming from Vested RSUs may be delayed or even forfeited, if he/she does not provide the information requested and required by the Company to perform the Cash Settlement and/or the Share Settlement, in particular, the information in § 6.3.

12.4 Each Participant is responsible for obtaining legal, tax and any other necessary advice before participating in the RSUP 2019 (US Inc.) and for evaluating the tax effects connected with the RSUP 2019 (US Inc.). Each Participant accepts and declares that he has not been advised by or on behalf of the Company with respect to his participation in the RSUP 2019 (US Inc.) (in particular, regarding legal and tax issues of such participation).

§ 13
TAXES, SOCIAL SECURITY AND COSTS

13.1 All taxes (including payroll taxes), social security contributions, further duties and costs accrued by the Participant in connection with his/her participation in the RSUP 2019 (US Inc.) shall be borne by each Participant. Each Participant is obliged to pay taxes relating to the respective RSUs granted/settled under the RSUP 2019 (US Inc.), or relating to a transfer (if permitted under these RSUP Terms & Conditions) of such RSUs by the Participant to a third party, to the competent tax authorities. Each Participant shall fully indemnify the Company in respect of all such liabilities and obligations against tax authorities.

13.2 MorphoSys US is entitled, if required by statutory law, to withhold payroll tax or any other taxes or duties or social security contributions to be paid by (or on behalf and account of) the Participant. This applies even after termination of the service relationship or employment relationship of a Participant with the Company. The Company is entitled to demand the full cooperation of the Participant even after his leave with respect to the withholding of taxes, social security contributions, other duties and costs in connection with the RSUP 2019 (US Inc.). The Participant undertakes to fully cooperate with the Company.

13.3 Withholdings mentioned above do not release the Participant from his responsibility and obligation to pay all taxes, social contributions, further

Page19/26

duties and costs being due and accruing in connection with his participation in the RSUP 2019 (US Inc.) or the allocation/grant, settlement or transfer of any RSUs.

13.4 The compensation and benefits under these RSUP Terms & Conditions are intended to comply with or be exempt from the requirements of Section 409A of the Code, and these RSUP Terms & Conditions will be interpreted and administered in a manner consistent with that intent. The preceding provision, however, shall not be construed as a guarantee by the Company of any particular tax effect to any Participant under these RSUP Terms & Conditions and shall not constitute an indemnity from the Company to any Participant. References to “termination of employment” and similar terms used in these RSUP Terms & Conditions mean, to the extent necessary to comply with Section 409A of the Code, the date that the Participant first incurs a “separation from service” within the meaning of Section 409A of the Code. Each payment under these RSUP Terms & Conditions shall be designated as a “separate payment” within the meaning of Section 409A of the Code.

§ 14
FORM REQUIREMENTS

14.1 Any legal statements and other notices in connection with the RSUP 2019 (US Inc.) (collectively the “Notices”) or any amendment of these RSUP Terms & Conditions (including an amendment of this § 14.1) shall be made in text form or electronic form (e.g. email) unless any other specific form is required by mandatory law or these RSUP Terms & Conditions.

Any Notice to be delivered to the Company shall be addressed by email to the Head of Human Resources of MorphoSys AG (currently: Silvia Dermietzel; email: Silvia.Dermietzel@morphosys.com. The Company shall communicate changes in the address set forth in the previous sentence as soon as possible to the Participants. In the absence of such communication, the address stated above shall remain in place.

Page20/26

14.2 Any Notice to be given to a Participant may be served by being sent to him/her by email or to his/her home or business address. Each Participant shall communicate changes of address as soon as possible to the Company.

§ 15
PROCESSING OF PERSONAL DATA

The Company processes personal data of the Participants in connection with the administration, implementation and settlement of the RSUP 2019 (US Inc.). Additional information regarding the processing of personal data in connection with the RSUP 2019 (US Inc.) is included in Exhibit 1 (Information on the Processing of Personal Data).

§ 16
GOVERNING LAW AND JURISDICTION

16.1 The RSUP 2019 (US Inc.), any RSUs granted thereunder and these RSUP Terms & Conditions shall be exclusively governed by, and be construed in accordance with, the laws of the Federal Republic of Germany, without regard to principles of conflicts of laws.

16.2 Any dispute, controversy or claim arising from or in connection with the RSUP 2019 (US Inc.), any RSUs granted thereunder or these RSUP Terms & Conditions or their validity shall be decided upon by the competent courts in Munich, Germany.

§ 17
FINAL PROVISIONS

17.1 In these RSUP Terms & Conditions, the headings are inserted for convenience only and shall not affect the interpretation of these RSUP Terms & Conditions; where a German term has been inserted in italics, it alone (and not the English term to which it relates) shall be authoritative for the purpose of the interpretation of the relevant English term in these RSUP Terms & Conditions. The terms “including” and “in particular” shall always mean “including, without limitation” and “in particular, without limitation”, respectively. Any reference made in these RSUP Terms & Conditions to any clauses without further indication of a law, an

Page21/26

agreement or another document shall mean clauses of these RSUP Terms & Conditions.

17.2 In the event that one or more provisions of these RSUP Terms & Conditions shall, or shall be deemed to, be invalid or unenforceable, the validity and enforceability of the other provisions of these RSUP Terms & Conditions shall not be affected thereby. In such case, the Company and each Participant agree to recognize and give effect to such valid and enforceable provision or provisions, which correspond as closely as possible with the commercial intent of the Parties. The same shall apply in the event that these RSUP Terms & Conditions contain any unintended gaps (unbeabsichtigte Lücken).

Page22/26

Planegg, October 2019

MorphoSys AG

* * * *

Page23/26

Exhibit 1

Exhibit 1

Information on the Processing of Personal Data
in connection with the Restricted Stock Unit Program 2019

(hereinafter referred to as “RSUP 2019 (US Inc.)”)
of MorphoSys AG

(hereinafter referred to as the“Company”)

In connection with the administration, processing and execution of the RSUP 2019 (US Inc.), the Company processes personal data of the beneficiaries (hereinafter also referred to as “Data Subjects”) in accordance with the EU General Data Protection Regulation (“GDPR”). Pursuant to the GDPR, the Company is obliged to provide the following information on the processing of personal data. All defined terms used in this information have the meaning assigned to them in the option conditions.

I. Responsibilities and Contact Information

The controller of the personal data pursuant to Art. 4 para. 7 is the Company:

MorphoSys AG

Semmelweisstraße 7

82152 Planegg

Germany

Telephone: +49 (0)89 899 27-0

Facsimile: +49 (0)89 899 27-222

E-Mail: info@morphosys.com

Website: www.morphosys.com

The Data Protection Officer of the Company can be contacted through:

MorphoSys AG

Data Protection Officer

Semmelweisstraße 7

82152 Planegg

Germany

or

Email: datenschutz@morphosys.com

Page24/26

Exhibit 1

II. Use of Personal Data by the Company

The Company processes personal data of the Data Subjects such as names, contact data, tax numbers and all other information necessary for the participation of a Data Subject in the RSUP 2019 (US Inc.) as well as for the administration, processing and execution of the RSUP 2019 (US Inc.) (processing purpose). The legal basis for data processing is Art. 6 Para. 1 (b) GDPR.

In addition, the Company processes personal data of the Data Subjects if and to the extent required by the law applicable to the Company (e.g., tax law). The legal basis for data processing in this respect is Art. 6 para. 1 (c) GDPR.

III. Transfer of Personal Data

The Company may disclose personal data to an external service provider (“External Service Provider”) commissioned or involved for the purposes of the administration, processing and/or execution of the RSUP 2019 (US Inc.) in order to support the processing of personal data for the processing purpose set out in Section II above. If and to the extent permitted by law, the Company may also commission other third parties to provide certain services, such as IT-services and legal services, for the processing purpose set out in Section II above and may disclose personal data to such third parties. These recipients provide their assistance or services to the Company under its control and direction and may have access to personal data to the extent necessary to provide their assistance or services.

In addition, the Company may, to the extent required and permitted by law, transfer personal data to domestic and foreign authorities or courts in order to fulfil legal obligations.

IV. Storage and Deletion of Personal Data

The Company processes the personal data within the framework of the participation of the Data Subjects in the RSUP 2019 (US Inc.). The Company deletes the personal data if it no longer needs it for the fulfilment of its contractual obligations under the RSUP 2019 (US Inc.) and if there are no legal storage obligations. In the event of a legal obligation to retain personal data, the Company shall restrict the processing of such personal data.

V. Rights of the Data Subjects

The Data Subjects may, at any time and free of charge, contact the Company or its Data Protection Officer directly with an informal notification in order to exercise their

Page25/26

Exhibit 1

rights under the GDPR. The Data Subjects have the right, subject to the legal requirements, the fulfilment of which is to be examined on a case-by-case basis, to request information on their personal data, any rectification or deletion of their personal data, information regarding restrictions on the processing of their personal data and they have the right to receive their personal data in a structured, generally used and machine-readable format.

The Data Subjects also have the right to object to the processing of their personal data, subject to the legal requirements, the fulfilment of which must be examined on a case-by-case basis.

In addition, Data Subjects have the right to lodge a complaint with a supervisory authority.

Page26/26

EX-5.1

Exhibit 5.1

MorphoSys AG ■ Postfach 16 58 ■ 82145 Planegg	MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany
United States Securities and Exchange Commission 450 Fifth Street N.W. Washington, DC 20549 United States of America	Telefon: Fax: Email: Internet:	+49 (0)89 899 27-0 +49 (0)89 899 27-222 info@morphosys.com www.morphosys.com
	November 5, 2019

Contact: Klaus de Wall

Phone: +49 89 89927 331

Form S-8

Ladies and Gentlemen,

I refer to the Registration Statement on Form S-8 (the “Registration Statement”) of MorphoSys AG, a German stock corporation (the “Company”), under the Securities Act of 1933 (the “Securities Act”). The Registration Statement relates to up to 127,357 ordinary shares, no par value, of the Company (the “Securities”), issued under the Restricted Stock Unit Program 2019 (US Inc.), offered to certain employees of MorphoSys US Inc.

I have examined and am familiar with (i) the Company’s Articles of Association and (ii) the corporate procedures relating to the issuance of the Securities. Upon the basis of the foregoing, and having satisfied myself as to such other matters of law and fact as I consider relevant for the purposes of this opinion, I advise you that, in my opinion, upon issuance, the Securities will have been legally issued, fully paid and non-assessable.

I express no opinion herein, on or with respect to, any law other than the laws of Germany, and I express no opinion on, or with respect to, the laws of the United States, any state thereof or any other laws, statutes, regulations or ordinances.

I hereby consent to the filing of this opinion as an exhibit to the Registration Statement and any reference to me therein. In giving such consent, I do not hereby admit that I am in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.

Management Board Dr. Jean-Paul Kress (Vorsitzender),
Dr. Markus Enzelberger,
Jens Holstein, Dr. Malte Peters Chairman of the Supervisory Board Dr. Marc Cluzel Bank details Commerzbank Sort code: 700 800 00 Account No.: 0349775600 IBAN: DE73 7008 0000 0349 7756 00 SWIFT (BIC): DRESDEFF700 Tax No. 9143/101/21259 VAT-ID. No. DE 15506 9821 Registered Office Planegg, Landkreis München Commercial register AG München HRB 121023

Very truly yours,

/s/ Charlotte Lohmann               

Charlotte Lohmann

General Counsel

MorphoSys AG

/s/ Klaus de Wall                       

Klaus de Wall

Head of Accounting & Tax

MorphoSys AG

- 2 -

EX-23.1

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated March 13, 2019 relating to the financial statements of MorphoSys AG and subsidiaries for the year ended December 31, 2018, which appears in the Annual Report of MorphoSys AG on Form 20-F for the year ended December 31, 2018.

Munich, Germany

November 5, 2019

PricewaterhouseCoopers GmbH

Wirtschaftsprüfungsgesellschaft

/s/ Stefano Mulas /s/ Holger Lutz

Stefano Mulas Holger Lutz

Wirtschaftsprüfer Wirtschaftsprüfer

(German Public Auditor) (German Public Auditor)